2.2 Recombinant Factor IX (rFIX) Product Sales and Market Size
2.2.1 BeneFIX Sales
2.2.2 Alprolix Sales
2.2.3 2014 Performance of rFIX Product Sales
2.2.4 rFIX Market Size
2.3 Recombinant Factor VII (rFVII) Product Sales and Market Size
2.3.1 NovoSeven Sales
2.3.2 Coagil VII Sales
2.3.3 rFVII Market Size
2.4 Recombinant Thrombin Product Sales and Market Size
2.5 Total Recombinant Coagulation Factor Market Size
3.1 Factor VIII Pipeline Changes and Drug Profile Updates
3.1.1 Wild-type, improved and biosimilar rFVIII
3.1.2 Long-acting rFVIII
3.2 Factor IX Pipeline Changes and Drug Profile Updates
3.2.1 Wild-type rFIX
3.2.2 Long-acting rFIX
3.3 Factor VII Pipeline Changes and Drug Profile Updates
3.3.1 Wild-type, improved and biosimilar rFVIIa
3.3.2 Long-acting rFVIIa
3.4 Pipeline Update for Other Recombinant Coagulation Factors
3.5 Pipeline Update for Alternative Procoagulants
3.5.1 Coagulation Factor Mimetics
3.5.2 Inhibitor Switch-off
3.5.3 Systemic Thrombin
3.5.4 Factor Xa Variants
3.5.5 Oral Procoagulants
3.6 Pipeline Update for Gene & Cell Therapy
3.6.1 Gene & Cell Therapy of Hemophilia B
3.6.2 Gene & Cell Therapy of Hemophilia A
3.6.3 Gene and Cell Therapy of Hemophilia A and B
3.7 Immune Tolerance Inducing (ITI) Agents
4.1 rFVIII Competitive Landscape Analysis
4.1.1 Wild-type, improved and biosimilar rFVIII Landscape
4.1.2 Long-acting rFVIII Landscape
4.2 rFIX Competitive Landscape Analysis
4.3 rFVII Competitive Landscape Analysis
4.4 Competitive Landscape of Other Recombinant Coagulation Factors
4.5 Competitive Landscape of Alternative Procoagulants for Systemic Use
4.6 Competitive Landscape of Gene & Cell Therapy for Hemophilia
4.7 Immune Tolerance Inducing (ITI) Agents
5.1 Coagulation Factor Portfolio Companies
5.1.1 Baxter
5.1.2 Novo Nordisk
5.1.3 CSL
5.1.4 Bayer HealthCare Pharmaceuticals
5.1.5 Pfizer
5.1.6 Octapharma
5.1.7 LFB
5.1.8 Biotest
5.1.9 The Medicines Company
5.2 Big Pharma & Biotech as New Entrants to Bleeding Disorder Field
5.2.1 Biogen Idec
5.2.2 Roche (Chugai)
5.2.3 AstraZeneca (MedImmune)
5.3 Specialty Pharma as New Entrants to Hemophilia Field
5.3.1 Shire
5.3.2 BioMarin Pharmaceutical
5.3.3 Emergent BioSolutions
5.3.4 OPKO Health
5.4 Biosimilar Companies
5.4.1 Generium Group
5.4.2 Aryogen
5.5 Protein Engineering Companies
5.5.1 Catalyst Biosciences
5.5.2 Pharming
5.5.3 The Chemo-Sero-Therapeutic Research Institute KAKETSUKEN
5.6 Gene & Cell Therapy Companies
5.6.1 uniQure
5.6.2 Spark Therapeutics
5.6.3 Dimension Therapeutics
5.6.4 Expression Therapeutics
5.6.5 Sangamo Biosciences
5.6.6 ReGenX
5.6.7 Sernova & Medicyte
5.6.8 Amarna Therapeutics
5.7 RNA Companies
5.7.1 Alnylam Pharmaceuticals
5.7.2 Arcturus Therapeutics
5.8 Immunology Companies
5.8.1 Apitope
5.8.2 Selecta Biosciences
5.8.3 EpiVax
6.1 Pipeline and Technology Overview and Trends
6.2 Short- and Mid-term Perspective of Recombinant Coagulation Factors
6.3 Key Product Profiles and Differentation Factors among Novel Products
6.4 Mid- and long-term perspective of new hemophilia treatments
6.5 Key Players in the Field
*If Applicable.